MAPK3 and cancer: Moreover, consistent with our previous results, which demonstrated the involvement of autocrine adenosine signaling in the cancer cell-mediated activation of MCs16, the present study shows that exposure to MRS1220, an antagonist of the adenosine A3 receptor significantly reduced ERK1/2 phosphorylation in both MC lines (Fig. 2).